Pralsetinib

Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively[1].

Product Specifications

CAS Number

[2097132-94-8]

Product Name Alternative

BLU-667

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

RET

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Blu667.html

Purity

99.98

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@@]1(OC)CC[C@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C

Molecular Formula

C27H32FN9O2

Molecular Weight

533.60

Precautions

H302, H315, H319, H335

References & Citations

[1]Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338.